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INTRODUCTION
Mycoplasma pneumoniae infections may be manifested in
upper respiratory tract, lower respiratory tract, or both, pre-
senting sore throat, hoarseness, fever, chills, cough, coryza,
malaise, wheezing, dyspnea, progression to bronchopneu-
monia or lobar pneumonia requiring hospitalization, and
extrapulmonary symptoms (1). This broad spectrum of symp-
toms cannot be differentiated from symptoms of the infec-
tions caused by other bacteria or viruses. The specific diag-
nosis M. pneumoniae infection is important because treatment
with  -lactam antibiotics is ineffective, whereas treatment
with macrolides or tetracyclines may markedly reduce the
duration of illness (2). However, reference laboratory meth-
ods for the diagnosis of M. pneumoniae infection have not
been established. 
Culture is time-consuming and relatively insensitive. The
introduction of polymerase chain reaction (PCR) for detec-
tion of M. pneumoniae in respiratory tract specimens has less-
ened the importance of culture, enabling rapid and sensitive
detection. However, PCR cannot differentiate colonization
from infection nor can detect organisms in the convalescent
phase (3-5).
Despite its drawbacks, for the use in immunosuppressed
persons who are unable to mount an antibody response, sero-
logic diagnosis of M. pneumoniae infections has long been the
cornerstone of diagnosis and epidemiologic study (1). The
complement fixation (CF) test was the standard serologic
method for the diagnosis of M. pneumoniae infection. The CF
test, using a glycolipid antigen, provides non-specific reac-
tions and therefore lacks sensitivity (6). Alternative formats
adapted for commercial serologic assays include indirect im-
munofluorescence assay (IFA), particle agglutination (PA)
assay, and enzyme-linked immunoassay (EIA). IFAs for M.
pneumoniae provide accurate, quantitative serological data,
but their interpretation is subjective and a fluorescence micro-
scope is necessary (1). The PA assay is the most widely used
method in Korea because it is easy to perform and give quan-
titative results with acceptable sensitivity. However, the am-
biguity in the interpretation of agglutination, non-specific
reactions, and inability to discriminate between IgG and
IgM are drawbacks of the PA assay for the diagnosis of M.
pneumoniae infection (7). Thus there is a need for EIA that
can detect IgG and IgM separately to distinguish current
from past infections. A few different EIA kits are now avail-
able in Korea, and some institutions have introduced them
recently. Changes in testing methods from PA to EIA could
be confusing to clinicians because of differences between PA
titer and EIA units; however, there is no available data for
the Korean patients. We analyzed the performance of four
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Evaluation of Four Commercial IgG- and IgM-specific Enzyme
Immunoassays for Detecting Mycoplasma pneumoniae Antibody: 
Comparison with Particle Agglutination Assay
Diagnosis of Mycoplasma pneumoniae infection is important due to its variable clin-
ical manifestations and absence of response to beta-lactams. Introduction of en-
zyme immunoassays (EIAs) for serologic diagnosis of M. pneumoniae has made
it possible to separate the analyses of specific IgG and IgM antibodies. We com-
pared four different commercial EIAs, ImmunoWELL IgG, IgM (GenBio), Medac
IgG, IgA, IgM (Medac), Platelia IgG, IgM (Sanofi Pasteur), and Ridascreen IgG,
IgA, IgM (r-Biopharm) with indirect particle agglutination assay (PA), Serodia-MycoII
(Fujirebio). We tested 91 specimens from 73 pediatric patients (2-17 yr) hospitalized
at a tertiary-care hospital between December 2005 and January 2006. The mea-
surements of IgM EIAs were correlated with PA titers (Spearman’s correlation coef-
ficient, from 0.89 to 0.92) with high concordance rates, ranging from 82.4% to 92.3%.
However, some negative IgM-EIA results in PA-positive specimens indicated that
serial samplings with convalescent sera would be necessary to confirm M. pneu-
moniae infection.
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commercial EIA kits sold in Korea and correlated the results
with PA assay results.
MATERIALS AND METHODS
Subjects and study design
Ninety-one sera from 73 children were requested for M.
pneumoniae antibody assay in the Department of Laboratory
Medicine from 1 December 2005 to 13 January 2006. The
age of study subjects ranged from 17 months to 17 yr (mean
5.3 yr), and 39 (53.4%) were male. They were admitted at
the Sanggye Paik Hospital, a tertiary-care hospital in Seoul
and were tested with a PA assay and four EIAs on the same
day. The medical records were reviewed, retrospectively. The
serum samples were drawn 5-15 days after the onset of their
respiratory or other symptoms. The patients were divided
into four groups based on their respiratory manifestation.
Group I comprised 37 patients with pneumonia proven by
abnormal chest radiographs. Group II comprised 14 patients
with upper or lower respiratory infections including naso-
pharyngitis, bronchitis, croup, and bronchiolitis with nor-
mal chest radiographs. Group III comprised 17 patients who
complained of aggravation of wheezing or dyspnea, with an
underlying diagnosis of asthma, without signs of other res-
piratory infections. Group IV comprised 5 patients with
extrapulmonary symptoms including: infectious mononu-
cleosis proven by Epstein Barr virus IgM anti-VCA (viral
capsid antigen) (1 patient), glomerulonephritis of unknown
cause (2 patients), and Henoch-Schonlein purpura (HSP) (2
patients). The positive rates of M. pneumoniae antibodies were
evaluated in each group with different serologic assays. If a
patient had two or more results, the higher value was select-
ed for the positive rates.
Particle agglutination assay
The Serodia-MycoII (Fujirebio Inc., Tokyo, Japan) test was
performed according to the manufacturer’s instructions. This
is a semi-quantitative agglutination assay using gelatin par-
ticles sensitized with a crude antigen mixture of M. pneumo-
niae (Mac strain). Using the serum diluent supplied, serum
samples were diluted serially giving final dilutions of 1:40
to 1:20,480. After 3-hr incubation at room temperature, but-
tons or compact, smooth rings of particles in the bottom of
the wells were read as negative agglutination patterns and a
more extensive ring as positive. The manufacturer recom-
mended that titers of 1:40 or more be regarded as positive. 
Enzyme immunoassays
Four different commercially available EIA kits containing
all reagents were evaluated using the protocols supplied. The
results were interpreted by the cutoff values established by
the manufacturer; each run was validated with a negative and
positive control included in the kits. Each manufacturer rec-
ommended retests after two or three weeks in cases with equi-
vocal results because they might indicate the onset of or the
resolution of infections. However, for simplicity of results, the
equivocal ranges were considered to be negative in this study.
ImmunoWELLTM M. pneumoniae IgG-, IgM-EIA (GenBio,
San Diego, CA, U.S.A.; purchased from DOW Biomedica)
is an indirect EIA, using a purified glycolipid of M. pneumo-
niae (strain FH) as the antigen. The ImmunoWELL IgM
test utilizes an IgG absorbent to eliminate interference due
to rheumatoid factors or residual human IgG antibodies.
The quantities of IgG and IgM antibodies in the serum were
calculated as the ratio of the sample absorbance value to cal-
ibrator absorbance value multiplied by the assigned value in
U/mL of the calibrator given in the insert of each kit. The
results were expressed as an arbitrary unit (AU/mL). The
cutoff of IgG antibody was 200 AU/mL, and the equivocal
range for IgM antibody was 770-950 AU/mL.
M. pneumoniae IgG-, IgA-, IgM- ELISA Medac (Medac
GmbH, Wedel, German; purchased from Naroo Ditech, Inc.)
uses a recombinant antigen mixture of M. pneumoniae. The
results of IgG and IgA antibodies were expressed in AU/mL
on the basis of a standard curve with one-point calibration;
the equivocal ranges were 9-11 AU/mL. After absorption of
IgG antibody or rheumatoid factor, semiquantitative IgM
antibody was measured as a ratio of sample optical density
(OD) to cutoff OD calculated from negative control mea-
surements. The ratio 0.9 to 1.1 was the equivocal range.
PlateliaTM M. pneumoniae IgG-, IgM-EIA (Sanofi Diagnos-
tica Pasteur, Marnes la Coquette, France; purchased from Bio-
Rad Laboratories) detects anti-M. pneumoniae antibodies by
indirect EIA. The microplate was coated with a solubilized
ultrasonicate of an M. pneumoniae culture containing enriched
P1 cytadhesin and other membrane proteins. The specimen
arbitrary unit (AU) values of IgG antibodies were determined
from the calibration curve and were interpreted as follows.
A value of <10 AU/mL for a single serum sample was con-
sidered insignificant, a value of 10 to 19 AU/mL was con-
sidered low, a value of 20 to 39 AU/mL was considered mod-
erate, and a value of >40 AU/mL was considered high. IgM-
EIA is a double-sandwich immunocapture EIA using a mic-
roplate coated with human anti- chain antibodies. The pres-
ence of specific IgM antibody in the specimen was determin-
ed by a ratio comparing the OD of the serum to the mean
OD of cutoff controls; a ratio >1.0 was regarded as positive.
The presence of IgM or high IgG was regarded as recent or
current infection according to the manufacture’s instructions.
Ridascreen
� M. pneumoniae IgG-, IgA-, IgM-EIA (r-Bio-
pharm, Darmstadt, Germany; purchased from Asan Pharma-
ceuticals)is a semiquantitative microtiter EIA for the detection
of M. pneumoniae IgG, IgM, or IgA antibodies. The results were
expressed in AU/mL on the basis of a calibration curve and
. .a lot-dependent correction factor. The equivocal ranges were:
23-31 AU/mL for IgG, 39-50 AU/mL for IgA, and 50-71
AU/mL for IgM.
Statistics
Degrees of agreements were evaluated with concordance
rates (%) and kappa values. Concordance rates were the pro-
portion of sera with concurrent positive or negative results in
both assays. The correlation between the PA titer and EIA
quantitative values were evaluated using the Spearman cor-
relations.
RESULTS
Positive rates of M. pneumoniae antibody in patient groups
Overall IgG positive rates were variable with the different
IgG EIAs and ranged from 37.0% to 71.2%. The positive
rates of IgM antibodies showed a narrower range from 41.1%
to 58.9%. Group I patients, patients with pneumonia proven
by abnormal chest radiographs, showed the highest number
of IgM-positive samples, which ranged from 62.2% to 78.4%
(Table 1).
Two patients in group I were diagnosed as viral pneumo-
nia; each patient with adenovirus pneumonia and respirato-
ry syncytial virus pneumonia showed a low PA titer and neg-
ative IgM EIAs. Five patients with extrapulmonary symp-
toms (group IV) were included, and 3 of them had positive
results with one or more test method. A patient with infec-
tious mononucleosis by Ebstein-Barr virus showed a positive
result with Medac IgM, equivocal results with Immuno-
WELL and Ridascreen IgM, and a negative result with Platelia
IgM. A patient with glomerulonephritis showed a PA titer of
1:160 and positive ImmunoWELL IgM result. A HSP patient
had a PA titer of 1:320 and positive IgM results from EIAs
except for Platelia IgM EIA.
Agreements between PA and four EIAs
Degrees of agreements among 4 kinds of EIAs were eval-
uated (Table 2). IgM-specific EIAs showed higher agreements
than IgG-specific EIAs. ImmunoWELL and Ridascreen had
highest agreements (IgM, 89.0% of concordance rate, 0.775
of kappa value; IgG, 79.1% of concordance rate, 0.542 of
kappa value). 
Degrees of agreements between PA and each EIA were eval-
uated based on each of PA titer, 1:40, 1:80, 1:160, 1:320, and
1:640. Three kinds of IgM-specific EIA had highest agree-
ments at PA titer 1:320 (concordance rate/kappa value, 92.3
%/0.839 for Medac; 91.2%/0.812 for Ridascreen; and 86.8
%/0.729 for ImmunoWELL). Platelia IgM EIA had better
agreement with PA titer 1:640 (86.8%; kappa value, 0.737)
than with PA 1:320 (82.4%; kappa value, 0.656). 
Comparison of IgG-specific EIAs with PA assays showed
a wide range of concordance rates. Each of IgG-specific EIAs
had highest agreement with PA assay at the different titer;
ImmunoWELL and Ridascreen had highest agreement with
PA titer, 1:160 (91.2%; kappa value, 0.774 and 74.7%; kappa
value, 0.446, respectively), Platelia did with PA titer, 1:320
(76.9%; kappa value, 0.528), and Medac did with PA titer,
1:640 (74.7%; kappa value, 0.498).
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Assay
No. (%) of patients positive
Group I (n=37) Group II (n=14) Group III (n=17) Group IV (n=5) Total
PA titer ≥1:320 27 (73.0) 8 (57.1) 6 (35.3) 2 (40.0) 43 (58.9)
IgG ImmunoWELL 31 (83.8) 8 (57.1) 10 (58.8) 3 (60.0) 52 (71.2)
Medac 19 (51.4) 3 (21.4) 4 (23.5) 1 (20.0) 27 (37.0)
Platelia 23 (62.2) 6 (42.9) 7 (41.2) 0 (0) 36 (49.3)
Ridascreen 25 (67.6) 8 (57.1) 7 (41.2) 2 (40.0) 43 (58.9)
IgM ImmunoWELL  26 (70.3) 6 (42.9) 6 (35.3) 2 (40.0) 40 (54.8)
Medac 25 (67.6) 6 (42.9) 6 (35.3) 2 (40.0) 39 (53.4)
Platelia 23 (62.2) 3 (21.4) 4 (23.5) 0 (0) 30 (41.1)
Ridascreen 29 (78.4) 7 (50.0) 6 (35.3) 1 (20.0) 43 (58.9)
IgA Medac 7 (18.9) 1 (7.1) 0 (0) 0 (0) 8 (11.0)
Ridascreen 12 (32.4) 2 (14.3) 1 (5.9) 1 (20.0) 16 (21.9)
Table 1. Positive rates of M. pneumoniae antibody according to patient groups
Group I, patients with radiograph-proven pneumonia; Group II, upper or lower respiratory infections with normal chest radiographs; Group III, aggra-
vation of wheezing or dyspnea in underlying asthma; Group IV, extrapulmonary symptoms.
Right upper areas are values of IgM. Left lower areas are those of IgG.
ImmunoWELL IgM
IgG
Medac Platelia Ridascreen
Table 2. Percent concordant rates (kappa value) among 4 kinds
of IgG- and IgM-specific enzyme immunoassays for anti-M. pne-
umoniae
ImmunoWELL 85.7 (0.710) 82.4 (0.651) 89.0 (0.775)
Medac 69.2 (0.424) 83.5 (0.674) 87.9 (0.749)
Platelia 71.4 (0.407) 71.4 (0.435) 82.4 (0.654)
Ridascreen 79.1 (0.542) 65.9 (0.336) 70.3 (0.398)798 S.J. Yoo, H.-J. Oh, B.-M. Shin
Medac IgA EIAs showed positive results in 12 specimens
and Ridascreen IgA EIA did in 19 specimens; 5 specimens
showed positive results with both IgA EIAs (76.9% of agree-
ment; kappa value, 0.192). 
Correlations between EIA quantitative results and PA titers
To examine the distribution of quantitative values, the
results of each EIA were compared to titers of PA assay. There
were significant correlations between the PA titers and the
results of each IgM EIA (Spearman’s correlation coefficient,
from 0.89 to 0.92) (Fig. 1). The results of IgG EIAs showed
no significant correlation with PA titers (coefficients of Spear-
man correlation, 0.51 for ImmunoWELL; 0.67 for Medac
and Platelia; 0.42 for Ridascreen). Correlations among EIAs
were more significant for IgM EIAs (coefficients of Spearman
correlation, ranging from 0.860 to 0.947) than IgG EIAs
(ranging from 0.488 to 0.808).
Comparisons of PA titers and EIA results
All eight specimens with negative PA results and 18 spec-
imens with a PA titer ≥1:5,120 showed concordant results
with all IgM assays. 
Nineteen specimens had PA titer 1:1,280 or 1:2,560, and
3 of them (15.8%) showed negative IgM results; a 5-yr-old
child with bronchitis had a PA titer of 1:2,560 and high IgG
but negative IgM results with Platelia (IgG, 100 AU/mL)
and ImmunoWELL (IgG, 3,589 AU/mL). Another 5-yr-old
child with a PA titer 1:1,280 and equivocal IgM result by Im-
munoWELL showed a positive conversion in a few days. The
third, a 7-yr-old boy with nasopharyngitis had a PA titer of
1:1,280 and equivocal or negative results with either Medac
or Platelia IgM assays. 
Twenty-one specimens from 16 patients had PA titers of
1:640 or 1:320. Among them, 8 specimens (38.1%) from 5
patients had no detectable IgM antibodies in two or more
EIAs, and 6 specimens (28.6%) were IgM-negative only with
the Platelia EIA. All of them had no significant change of PA
titers in serial specimens. Among the six cases with negative
Platelia IgM results, one case had pneumonia with a high
IgG value (96 AU/mL, suggesting high risk), another case
was diagnosed as HSP without follow-up specimen, and the
remaining four cases were patients with pneumonia or asthma.
Twenty-two patients (25 specimens) presented with PA
titers from 1:40 to 1:160. Most of these cases had negative
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Fig. 1. Spearman correlation of M. pneumoniae IgM titers obtained by various IgM assays in relation to particle agglutination assay titers.
All correlations were significant (p<0.001).
M
e
d
a
c
 
I
g
M
 
(
c
u
t
o
f
f
 
r
a
t
i
o
)
6
5
4
3
2
1
0
N 40 80
160
320
640
1,280
2,560
5,120
10,240
20,480
PA titer
R=0.92
P
l
a
t
e
l
i
a
 
I
g
M
 
(
c
u
t
o
f
f
 
r
a
t
i
o
)
6
5
4
3
2
1
0
N 40 80
160
320
640
1,280
2,560
5,120
10,240
20,480
PA titer
R=0.92
R
i
d
a
s
c
r
e
e
n
 
I
g
M
 
(
A
U
/
m
L
)
3,000
2,500
2,000
1,500
1,000
500
0
N 40 80
160
320
640
1,280
2,560
5,120
10,240
20,480
PA titer
R=0.92EIAs for Diagnosis of Mycoplasma pneumoniae  799
IgM EIAs, and some had positive IgG EIAs. ImmunoWELL
IgM EIA detected IgM antibodies from two patients with a
PA titer of 1:160 that manifested clinically as pneumonia
and glomerulonephritis, respectively. Ridascreen IgM EIA
detected IgM antibodies from two patients with pneumonia
with a PA titer of 1:160 and another with 1:40. Medac IgM
EIA detected IgM from a patient with croup and a PA titer
of 1:80.
The review of medical record for 73 patients revealed that
43 patients had the paired PA tests at an interval of 5 to 15
days. Nine patients presented PA titer changes of four-fold or
more and, 14 specimens from them were included in this
comparison study. All of them showed positive IgM anti-
bodies with 4 kinds of EIAs, and 2 of them exhibited the
seroconversions of IgG antibodies with 2 EIAs. 
DISCUSSION
It is well known that M. pneumoniae causes 40% or more
cases of community-acquired pneumonia and as many as
18% of cases requiring hospitalization in children (1). Recent
epidemiologic studies indicated that M. pneumoniae are fre-
quently involved as causative agents in upper or lower res-
piratory tract infections including common colds, pharyn-
gitis, bronchitis, wheezing, and extrapulmonary disease in
children aged less than 5 yr as well as in school ages and
throughout the year with periodic epidemics at 3-7 yr inter-
vals (8). M. pneumoniae had been isolated from the respirato-
ry tract of 20-50% of asthmatic patients with acute exacer-
bations and patients with chronic stable asthma (8). Prin-
cipi et al. evaluated the incidences of acute M. pneumoniae
infection in 613 Italian children aged 2-14 yr with commu-
nity-acquired lower respiratory infections. EIA for M. pneu-
moniae-specific IgG/IgM antibodies indicated that M. pneu-
moniae was the causative agent in 25.6% of acute bronchitis
(ranged from 19.3 to 52.9% over age groups), 28.0% of
wheezing (22.6% to 50.0%), and 33.9% of pneumonia with
infiltration on chest radiograph (20.0% to 54.6%) (9). They
also reported that 24.2% of pharyngitis were due to M. pneu-
moniae (8). Layani-Milon et al. reported that a PCR-hybridiza-
tion assay in nasal swab detected M. pneumoniae from 7.3%
of children with influenza-like upper respiratory infections,
ranging from 2.0 to 10.1% over the five period (10). Our
patients who were diagnosed as pneumonia with abnormal
chest radiograph (group I) showed higher IgM positive rates
than previous reports; ranging from 62.2% to 78.4% with
4 kinds of EIAs (Table 1). Platelia detected IgM antibodies
from 21.4% of group II patients (upper or lower respiratory
infection except pneumonia with infiltrations) and 23.5%
of group III patients (acute exacerbation of asthma), and other
3 IgM EIAs detected IgM antibodies more frequently com-
pared with Platelia in groups II and III or than previous re-
ports in group II. Because our study was performed on 73
children within 2 winter-months for the purpose of compari-
son of methods, the possibility of M. pneumoniae epidemics
and the small number of study participants could explain
the higher positive rates. The positive or equivocal reactions
of IgM EIAs in a patient with infectious mononucleosis sug-
gested false positive activity due to heterophil antibodies.
More specimens need to be evaluated for the heterophil anti-
body reactions to fully understand these findings. A patient
with glomerulonephritis and a patient with HSP had a pos-
itive reaction in one or more IgM EIAs. These cases could
not be discriminated from true M. pneumoniae infections; in
fact, there have been many cases reported as glomerulonephri-
tis and other systemic manifestations in patients with M.
pneumoniae (11, 12).
The PA titer for the best sensitivity and specificity for the
diagnosis of M. pneumoniae infections was controversial in
previous reports. A comparison study of PA titer, culture,
and PCR indicated a PA titer ≥1:160 had the greatest diag-
nostic power in a child with respiratory symptoms based on
good receiver-operating characteristic areas under the curve
(13). Other investigators suggested a PA titer ≥1:640 (14,
15). Choi et al. evaluated the mycoplasma antibody titer from
177 healthy children with the PA assay used in our study;
46.3% of healthy children were PA-positive, and their titers
were 1:320 or less (15). In our series, Serodia MycoII showed
high sensitivity presenting positive results in 83 of 94 spec-
imens (91.2%) with the manufacturer’s cutoff, 1:40. How-
ever, most of 25 specimens with PA titers ≤1:160 were nega-
tive for IgM antibodies with EIAs but positive for IgG anti-
bodies. We evaluated the agreements of EIAs with each titer
of PA and 3 of 4 IgM EIAs had the best concordance with
PA titer 1:320. They showed good concordance rates, 82.4%
to 92.3% and their quantitative results were significantly
correlated. However, IgG EIAs demonstrated a lower con-
cordance and no significant correlations with PA titers. These
observations supported the manufacturer’s claim that Sero-
dia MycoII detects exclusively M. pneumoniae-specific IgM.
However, some cases suggested that IgG antibodies result-
ed PA-positive reactions, especially at low PA titers. 
A few specimens in our study showed IgM negativity in
spite of high PA titers (≥1:1,280) and similar findings were
observed in previous reports (7). Our cases showed high IgG
titers in the same specimen or positive conversions of IgM
antibodies in follow-up specimens. Yoon et al. reported pos-
itive rates of M. pneumoniae antibodies reached a peak from
7th to 9th day and went down after 16th day (16). Some
specimens in our series were obtained 10 days or more after
the onset of symptoms and follow-up specimens at an inter-
val less than 7 days. It could not be ruled out that late sam-
pling times decreased the IgM EIA positive rates and increas-
ed the IgG EIA positive rates in PA-positive specimens (17).
The first blood specimen within 10 days of the onset of ill-
ness and convalescent serum at intervals of 7 to 10 days are
important for demonstrating a significant rise in antibodytiters (17, 18). For Platelia IgG EIA, the manufacturer’s guide-
lines indicated that high IgG values (>40 AU/mL) could be
interpreted as a current infection and it compensated for the
relatively low sensitivity of the Platelia IgM assay. Use of
EIAs enabled the simultaneous testing of specific IgG and
IgM antibodies, and it was helpful for assessing some IgM
negative- and IgG positive cases as past infections, especial-
ly for the patients with low PA titers. However, in the clini-
cal situation of a single negative IgM EIA result, another
specimen for paired evaluation was supposed to be necessary
to establish the diagnosis of current infection of M. pneumo-
niae. This comparison study included 34 paired sera from
16 patients, and two of them showed positive conversions of
IgG antibodies. Further studies with large numbers of paired
sera might show the possibility of IgG EIAs as a supplemen-
tary role for confirming current infections of M. pneumoniae.
Nineteen patients (20.9%) had IgA antibodies with one
or two available IgA EIA kits, and all of them had positive
IgM results suggesting the specificities of IgA EIAs for cur-
rent M. pneumoniae infections. However, their clinical useful-
ness was hampered by low positive rates in our pediatric pa-
tients. Granstrom et al. reported that IgA EIA was useful for
early diagnosis of acute infection in adults due to its earlier
response compared to IgM and occasional lack of IgM forma-
tion in adults (19). They reported that specific IgA antibod-
ies developed more regularly and more rapidly than IgM anti-
bodies, and IgA titers also started to decrease earlier than IgM
antibodies or the late-peaking IgG responses. All of our pa-
tients with positive IgA results had high IgM titers, suggest-
ing early phases of infections. Late sampling was considered
as a possible cause of low positive rates of IgA antibodies in
our patients. Presentations in post-acute stages of infections
at our tertiary-care hospital was thought to have caused
missing the early phase to obtain IgA-positive result.
An assay format other than serologic methods was not per-
formed for the determination of the specificity and sensitiv-
ity. Even though there is no reference method for the diagno-
sis of M. pneumoniae infection, a study with a different method,
such as PCR or culture, would provide more informative data.
In conclusion, IgM EIAs for the detection of M. pneumoni-
ae infection showed good agreements with the PA assay, and
their quantitative results were well correlated. Confirmation
of M. pneumoniae infection in a case with negative IgM anti-
bodies required a serial sampling with convalescent serum.
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